Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 24 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/29/2008 First Published: 10/21/2005


1.		Phase I/II Study of Nonmyeloablative Conditioning Comprising Busulfan, Fludarabine, and Total-Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 75				NCI				OHSU-HEM-05011-L OHSU-210, NCT00245037

Last Modified: 9/29/2008 First Published: 2/26/2008


2.		Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				70 and under				Other				BCM-H-19386 BCM-FAB, H 19386, NCT00625144


3.		A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				CLBH589B2102 NCT00621244


4.		Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				0 to 55				Other				8717 NCT00673114


5.		A Phase II Study of Umbilical Cord Blood Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 70				Other				UCBT001 NCT00676806


6.		T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Not specified				Other				11300A NCT00683046


7.		Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				MPC-2130-04-002 NCT00387153

Last Modified: 5/27/2008 First Published: 1/9/2008


8.		Phase I Study of Umbilical Cord Blood (UCB)-Derived CD25+CD4+ T-Regulatory Cell Infusion After Nonmyeloablative UCB Transplantation in Patients With Advanced Hematologic Cancer and Other Disorders

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				12 to 70				NCI				UMN-2007LS022 UMN-2007LS022, UMN-MT2006-01, UMN-0701M00303, UMN-12559, UMN-6220-04, NCT00602693


9.		A Study of Oral PF-02341066, a c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, in Patients With Advanced Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				A8081001 NCT00585195


10.		Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				B1311002 SNX-5422-CLN1-002, NCT00595686

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute